{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:57:01Z","timestamp":1787907421703,"version":"build-2784847793"},"reference-count":37,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union Seventh Framework Program","award":["602295"],"award-info":[{"award-number":["602295"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Angiotensin-converting enzyme inhibitors, such as enalapril, are foundational in treating pediatric heart failure. However, they are often administered off-label to young children using extemporaneous formulations. This study, conducted as part of the EU-funded Labeling of Enalapril from Neonates up to Adolescents (LENA) project, aimed to evaluate the acceptability and palatability of an age-appropriate enalapril orodispersible minitablet (ODMT). These factors are critical for ensuring adherence, efficacy, and safety in pediatric patients. Methods: An 8-week trial was conducted in children with heart failure caused by dilated cardiomyopathy or congenital heart disease. Enalapril ODMTs (0.25 mg or 1.0 mg) were dose-titrated and administered to 38 children aged 0\u20136 months and 22 children aged 6 months to 6 years. This study aimed to assess its acceptability and palatability, key factors contributing to adherence, and therefore, efficacy and safety. Results: Across all 169 assessments in 38 children aged 0\u20136 months and 22 aged 6 months to 6 years, complete or partial swallowability was observed, and the acceptability rate was 100%. There were no cases of choking, inhalation\/coughing, or spitting out. A favorable or neutral rating was observed in 96% of palatability assessments based on observations of facial expressions. Acceptability and palatability were higher in subjects aged 6 months\u20136 years than 0\u20136 months, with no significant influence from repeated administration. Conclusions: Enalapril ODMTs are widely accepted and well-tolerated among young children, including neonates, with heart failure. These findings suggest that ODMTs are a suitable and effective method for administering pediatric medicinal products.<\/jats:p>","DOI":"10.3390\/jcm14030915","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:42:37Z","timestamp":1738237357000},"page":"915","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Acceptability and Palatability of Novel Orodispersible Minitablets of Enalapril in Children up to the Age of 6 with Heart Failure"],"prefix":"10.3390","volume":"14","author":[{"given":"Milica","family":"Lazic","sequence":"first","affiliation":[{"name":"Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, 11129 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Djukic","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Children\u2019s Hospital, 11129 Belgrade, Serbia"},{"name":"Department of Pediatrics, Faculty of Medicine, University of Belgrade, 11129 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladislav","family":"Vukomanovic","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, University of Belgrade, 11129 Belgrade, Serbia"},{"name":"Department of Cardiology, Institute of Mother and Child Health \u201cDr Vukan \u010cupi\u0107\u201d, 1070 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Bijelic","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Children\u2019s Hospital, 11129 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emina","family":"Obarcanin","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacy and Pharmacotherapy, Heinrich-Heine-Universitaet D\u00fcsseldorf, 40225 Duesseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Bajcetic","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, 11129 Belgrade, Serbia"},{"name":"Department of Cardiology, University Children\u2019s Hospital, 11129 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Castaldi, B., Cuppini, E., Fumanelli, J., Di Candia, A., Sabatino, J., Sirico, D., Vida, V., Padalino, M., and Di Salvo, G. (2023). Chronic Heart Failure in Children: State of the Art and New Perspectives. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072611"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11886-020-01383-1","article-title":"Important Considerations in Pediatric Heart Failure","volume":"22","author":"Wall","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00228-005-0981-y","article-title":"Off Label and Unlicensed Drugs Use in Paediatric Cardiology","volume":"61","author":"Bajcetic","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.phrs.2011.01.016","article-title":"The Development of Medicines for Children: Part of a Series on Pediatric Pharmacology, Guest Edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni","volume":"64","author":"Rocchi","year":"2011","journal-title":"Pharmacol. Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zuccari, G., Alfei, S., Marimpietri, D., Iurilli, V., Barabino, P., and Marchitto, L. (2022). Mini-Tablets: A Valid Strategy to Combine Efficacy and Safety in Pediatrics. Pharmaceuticals, 15.","DOI":"10.3390\/ph15010108"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"J\u00eetc\u0103, C.-M., J\u00eetc\u0103, G., \u0150sz, B.-E., Pu\u0219ca\u0219, A., and Imre, S. (2023). Stability of Oral Liquid Dosage Forms in Pediatric Cardiology: A Prerequisite for Patient\u2019s Safety\u2014A Narrative Review. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041306"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Malkawi, W.A., AlRafayah, E., AlHazabreh, M., AbuLaila, S., and Al-Ghananeem, A.M. (2022). Formulation Challenges and Strategies to Develop Pediatric Dosage Forms. Children, 9.","DOI":"10.3390\/children9040488"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00228-007-0390-5","article-title":"Paediatric Clinical Pharmacology\u2014At the Beginning of a New Era","volume":"64","author":"Hoppu","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/157488607779315471","article-title":"Quality, Safety and Efficacy in the \u2018Off-Label\u2019 Use of Medicines","volume":"2","author":"Kairuz","year":"2008","journal-title":"Curr. Drug Saf."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Landwehr, C., Richardson, J., Bint, L., Parsons, R., Sunderland, B., and Czarniak, P. (2019). Cross-Sectional Survey of off-Label and Unlicensed Prescribing for Inpatients at a Paediatric Teaching Hospital in Western Australia. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210237"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.2174\/1381612821666150901105925","article-title":"Availability of Oral Formulations Labeled for Use in Young Children in Serbia, Germany and the USA","volume":"21","author":"Bajcetic","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2471\/BLT.08.053645","article-title":"What Essential Medicines for Children Are on the Shelf?","volume":"87","author":"Robertson","year":"2009","journal-title":"Bull. World Health Organ."},{"key":"ref_13","unstructured":"(2025, January 11). European Medicines Agency Revised Priority List for Studies on Off-Patent Paediatric Medicinal Products. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/other\/revised-priority-list-studies-patent-paediatric-medicinal-products_en.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"M\u00fcnch, J., Kloft, C., Farhan, M., Fishman, V., Leng, S., Bosse, H.M., and Klingmann, V. (2023). Acceptability, Swallowability, Palatability, and Safety of Multiple Film-Coated Mini-Tablets in Children Aged \u22652\u2013<7 Years: Results of an Open-Label Randomised Study. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020701"},{"key":"ref_15","unstructured":"World Health Organization (2017). The Selection and Use of Essential Medicines: Report of the WHO Expert Committee, World Health Organization."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ijpharm.2014.03.057","article-title":"Regulatory Perspectives on Acceptability Testing of Dosage Forms in Children","volume":"469","author":"Kozarewicz","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_17","unstructured":"WHO (2012). Expert Committee Annex 5 Development of Paediatric Medicines: Points to Consider in Formulation, WHO. Technical Reports No. 970 2012, Forthy-Six."},{"key":"ref_18","first-page":"150","article-title":"Formulation and Evaluation of Carbamazepine Fast Disintegrating Tablets","volume":"72","author":"Comoglu","year":"2010","journal-title":"Die Pharm. Ind."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1080\/10837450.2019.1615090","article-title":"Orally Disintegrating Tablets and Orally Disintegrating Mini Tablets\u2013Novel Dosage Forms for Pediatric Use","volume":"24","author":"Comoglu","year":"2019","journal-title":"Pharm. Dev. Technol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2471\/BLT.16.171967","article-title":"Medicines for Children: Flexible Solid Oral Formulations","volume":"95","author":"Orubu","year":"2017","journal-title":"Bull. World Health Organ."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1208\/s12249-016-0639-3","article-title":"Acceptability of Mini-Tablets in Young Children: Results from Three Prospective Cross-over Studies","volume":"18","author":"Klingmann","year":"2017","journal-title":"AAPS Pharmscitech"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/17425247.2018.1420054","article-title":"10 Years EU Regulation of Pediatric Medicines\u2013Impact on Cardiovascular Drug Formulations","volume":"15","author":"Thabet","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1542\/peds.2008-2059","article-title":"Minitablets: New Modality to Deliver Medicines to Preschool-Aged Children","volume":"123","author":"Thomson","year":"2009","journal-title":"Pediatrics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jpeds.2013.07.014","article-title":"Favorable Acceptance of Mini-Tablets Compared with Syrup: A Randomized Controlled Trial in Infants and Preschool Children","volume":"163","author":"Klingmann","year":"2013","journal-title":"J. Pediatr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jpeds.2015.07.010","article-title":"Acceptability of Uncoated Mini-Tablets in Neonates\u2014A Randomized Controlled Trial","volume":"167","author":"Klingmann","year":"2015","journal-title":"J. Pediatr."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mitsui, N., Hida, N., Kamiya, T., Yamazaki, T., Miyazaki, K., Saito, K., Saito, J., Yamatani, A., Ishikawa, Y., and Nakamura, H. (2022). Swallowability of Minitablets among Children Aged 6\u201323 Months: An Exploratory, Randomized Crossover Study. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010198"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/archdischild-2011-300958","article-title":"Acceptance of Uncoated Mini-Tablets in Young Children: Results from a Prospective Exploratory Cross-over Study","volume":"97","author":"Spomer","year":"2012","journal-title":"Arch. Dis. Child."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bijelic, M., Djukic, M., Vukomanovic, V., Parezanovic, V., Lazic, M., Pavlovic, A., Popovic, S., Parezanovic, M., Stefanovic, I., and Djordjevic, S. (2024). Clinical and Hemodynamic Outcomes with Enalapril Orodispersible Minitablets in Young Children with Heart Failure Due to Congenital Heart Disease. J. Clin. Med., 13.","DOI":"10.3390\/jcm13174976"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100393","DOI":"10.1016\/j.conctc.2019.100393","article-title":"Orodispersible Minitablets of Enalapril for Use in Children with Heart Failure (LENA): Rationale and Protocol for a Multicentre Pharmacokinetic Bridging Study and Follow-up Safety Study","volume":"15","author":"Bajcetic","year":"2019","journal-title":"Contemp. Clin. Trials Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/cpdd.728","article-title":"Relative Bioavailability of Enalapril Administered as Orodispersible Minitablets in Healthy Adults","volume":"9","author":"Burckhardt","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2015.02.068","article-title":"Can Preschool-Aged Children Swallow Several Minitablets at a Time? Results from a Clinical Pilot Study","volume":"485","author":"Kluk","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"121501","DOI":"10.1016\/j.ijpharm.2022.121501","article-title":"Paediatric Specific Dosage Forms: Patient and Formulation Considerations","volume":"616","author":"Khan","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijpharm.2013.07.054","article-title":"What Can We Do to Make Antihypertensive Medications Taste Better for Children?","volume":"457","author":"Ferrarini","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2710.2011.01330.x","article-title":"Palatability of Crushed \u03b2-Blockers, Converting Enzyme Inhibitors and Thiazides","volume":"37","author":"Zgraggen","year":"2012","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Golhen, K., Buettcher, M., Kost, J., Huwyler, J., and Pfister, M. (2023). Meeting Challenges of Pediatric Drug Delivery: The Potential of Orally Fast Disintegrating Tablets for Infants and Children. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041033"},{"key":"ref_36","first-page":"370","article-title":"Recent Formulation Advances and Preparation of Orally Disintegrating Tablets","volume":"26","author":"Ejeta","year":"2022","journal-title":"Int. J. Pharm. Compd."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Omidian, H., and Mfoafo, K. (2023). Exploring the Potential of Nanotechnology in Pediatric Healthcare: Advances, Challenges, and Future Directions. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15061583"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/915\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:39:01Z","timestamp":1759919941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14030915"],"URL":"https:\/\/doi.org\/10.3390\/jcm14030915","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]}}}